Navigation Links
Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition
Date:1/15/2014

Rochester, NY (PRWEB) January 15, 2014

The Microcompetition with Foreign DNA theory explains how latent viruses can cause a major disease. One of these latent viruses is the Epstein Barr Virus (EBV), and one of these diseases is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys the body’s joints. As predicted by the theory, a study found that RA patients have high concentrations of EBV DNA in their bodies (1).

What is Microcompetition?

Dr. Hanan Polansky discovered that foreign DNA fragments, called N-boxes, cause most major diseases. When the foreign N-boxes belong to a virus, Microcompetition between the viral DNA and the human DNA can lead to disease. As predicted by Dr. Hanan Polansky, many studies found fragments of DNA that belong to these viruses in many diseased tissues, such as tumors, clogged arteries (arterial plaque), and specifically arthritic joints.

Dr. Hanan Polansky's discovery has important implications. It suggests that medicines can cure and even prevent major diseases, such as rheumatoid arthritis, by targeting the foreign DNA fragments in the human body.

As predicted by the Microcompetition theory, the study on EBV and RA showed that patients with rheumatoid arthritis have high numbers of EBV. “Research has revealed increased viral load, high titers of EBV-directed antibodies, and decreased cell-mediated
control of EBV in RA patients compared to healthy controls (1).”

What is rheumatoid arthritis?

Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys the body’s joints. The disease “causes premature mortality, disability and compromised quality of life (3).” In addition, study authors wrote that RA “prevalence in women is twofold to fourfold that in men. RA has enormous personal, social, and economic impact; women with RA have overall mortality rates 2.3-fold those in age-matched controls… (2).”

The currently accepted view by the medical community says that there is no known cure for RA.

The CBCD believes that the medical community should learn more about Microcompetition. In addition, the CBCD believes that interrupting the process of Microcompetition, as described by Dr. Hanan Polansky in his ground-breaking book, “Microcompetition with Foreign DNA and the Origin of Chronic Disease,” should be the basis for new therapies targeting RA.

To learn more about Dr. Hanan Polansky’s research and the Theory of Microcompetition with Foreign DNA, visit: http://www.cbcd.net.

Reference:

(1) Epstein-Barr Virus in Systemic Autoimmune Diseases. Published on August 24, 2013.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3766599/#__ffn_sectitle

(2) Epstein–Barr virus and rheumatoid arthritis: is there a link? Published on January 16, 2013
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526553/

(3) CDC - Rheumatoid Arthritis. Last Updated on November 19, 2012.
http://www.cdc.gov/arthritis/basics/rheumatoid.htm

(4) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
     http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11487598.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
2. Nature Materials study: Graphene invisible to water
3. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
4. Nature Materials study: Boosting heat transfer with nanoglue
5. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
6. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
7. New Study: Valtrex (Valacyclovir) Side Effects Target the Brain; polyDNA Suggests a Natural Herpes Remedy
8. Study: FOLFIRINOX Followed by Chemoradiation Shows Substantial Activity in Locally Advanced Pancreatic Cancer
9. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
10. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
11. Study: Higher Hepatitis C Infection During Acupuncture in Asian Americans; polyDNA Recommends That Doctors Prescribe Gene-Eden-VIR against HCV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):